|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Via a 14;18 chromosomal translocation, BCLP is overexpressed in most follicular lymphomas as well as some other non-Hodgkin's lymphomas, and it has also been documented in other nonlymphomatous malignancies.
|
7590697 |
1995 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
BCLP was detected in 47 of 126 cases (37%) including 32 AC (44%), 10 SCC 925%), two ASC (40%), and three LCC (38%).
|
7590697 |
1995 |
|
Lymphoma, Follicular
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Via a 14;18 chromosomal translocation, BCLP is overexpressed in most follicular lymphomas as well as some other non-Hodgkin's lymphomas, and it has also been documented in other nonlymphomatous malignancies.
|
7590697 |
1995 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that BCLP might be associated with cell morphology and a regulation of growth pattern of tumor.
|
11394883 |
2001 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We evaluated if BCLP mRNA detection in the blood is useful in gynecologic malignancies.
|
11724320 |
2001 |
|
Malignant tumor of cervix
|
0.010 |
Biomarker
|
disease |
BEFREE |
Beta-casein-like protein (BCLP) is a putative protein on cervical cancer and exhibits immunological characteristics similar to those of bovine beta-casein.
|
11724320 |
2001 |
|
Cervix carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Beta-casein-like protein (BCLP) is a putative protein on cervical cancer and exhibits immunological characteristics similar to those of bovine beta-casein.
|
11724320 |
2001 |
|
cervical cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Beta-casein-like protein (BCLP) is a putative protein on cervical cancer and exhibits immunological characteristics similar to those of bovine beta-casein.
|
11724320 |
2001 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
CAC1 is highly expressed in cancer tissues and cancer cell lines.
|
19829063 |
2009 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
CAC1 is highly expressed in cancer tissues and cancer cell lines.
|
19829063 |
2009 |
|
Alzheimer's Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our findings showed that the expression level of CAC1 in the hippocampus of AD patients was significantly lower than that of normal controls.
|
22415352 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We demonstrated that CAC1 is over-expressed in malignant tumors, and cellular CAC1 depletion resulted in cancer growth suppression.
|
22903020 |
2012 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that miR-199a-5p can regulate CAC1 and function as a tumor suppressor in colorectal cancer.
|
22903020 |
2012 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We further identified CAC1, a cell cycle-related protein expressed in colorectal cancer, as a miR-199a-5p target.
|
22903020 |
2012 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We further identified CAC1, a cell cycle-related protein expressed in colorectal cancer, as a miR-199a-5p target.
|
22903020 |
2012 |
|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Therefore, the potential roles of deoxycholic acid in carcinogenesis are to decrease miR-199a-5p expression and/or increase the expression of CAC1, which contributes to tumorigenesis in patients with CRC.
|
22903020 |
2012 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, our study provides the first evidence that CAC1, associated with LSD1, functions as an ERα corepressor, implicating a potential antitumor target in ERα-positive breast cancer.
|
23178685 |
2013 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, our study provides the first evidence that CAC1, associated with LSD1, functions as an ERα corepressor, implicating a potential antitumor target in ERα-positive breast cancer.
|
23178685 |
2013 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
For example, among those with an ASCVD risk of <15% and who had an SBP of either 120 to 139 mm Hg or 140 to 159 mm Hg, respectively, we found increasing hazard ratios for events with CAC 1 to 100 (1.7 [95% confidence interval, 1.0-2.6] or 2.0 [1.1-3.8]) and CAC >100 (3.0 [1.8-5.0] or 5.7 [2.9-11.0]), all relative to CAC=0.
|
27881560 |
2017 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Cox models were used to obtain hazard ratios according to CAC category, or per 1 SD log2[CAC+1], adjusted for vascular risk factor, APOE-ε4, with or without exclusion of interim stroke or cardiovascular disease.
|
28465455 |
2017 |
|
Presenile dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
1 SD higher log2[CAC+1] was associated with 24% (95% confidence interval, 8%-41%; <i>P</i>=0.002) increase in dementia risk.
|
28465455 |
2017 |
|
Dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
1 SD higher log2[CAC+1] was associated with 24% (95% confidence interval, 8%-41%; <i>P</i>=0.002) increase in dementia risk.
|
28465455 |
2017 |
|
Adenoma of large intestine
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Similarly, the adjusted odds ratios (95% confidence interval) for any CRA comparing participants with CAC 1 to 100 and CAC>100 with those with no CAC were 1.26 (1.00-1.6) and 2.07 (1.31-3.26), respectively.
|
28471937 |
2018 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The relative adjusted subhazard ratio (aSHR) for CAC 1 to 100, 101 to 400, and >400 was 2.2, 3.8, and 5.9 for MI; 1.2, 1.4, and 1.9 for stroke; 1.4, 2.0, and 2.8 for MACE; and 1.2, 1.5 and 2.1 for death (p < 0.0001).
|
29153576 |
2018 |
|
Cerebrovascular accident
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The relative adjusted subhazard ratio (aSHR) for CAC 1 to 100, 101 to 400, and >400 was 2.2, 3.8, and 5.9 for MI; 1.2, 1.4, and 1.9 for stroke; 1.4, 2.0, and 2.8 for MACE; and 1.2, 1.5 and 2.1 for death (p < 0.0001).
|
29153576 |
2018 |